Mavoko, Hypolite Muhindo <br/><br/>
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.  [electronic resource] 

 -  The Lancet. Global health  01 2017 
 - e60-e68 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2214-109X 
<br/><br/><label>Standard No.: </label>10.1016/S2214-109X(16)30236-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amodiaquine--therapeutic use<br/>Anorexia<br/>Antimalarials--therapeutic use<br/>Artemether, Lumefantrine Drug Combination<br/>Artemisinins--therapeutic use<br/>Child, Preschool<br/>Clindamycin--therapeutic use<br/>Democratic Republic of the Congo<br/>Drug Combinations<br/>Ethanolamines--therapeutic use<br/>Female<br/>Fluorenes--therapeutic use<br/>Humans<br/>Infant<br/>Malaria, Falciparum--drug therapy<br/>Male<br/>Quinine--therapeutic use<br/>Treatment Outcome<br/>Uganda